Campbell & CO Investment Adviser LLC Invests $730,000 in Insulet Co. (PODD) Stock

Campbell & CO Investment Adviser LLC acquired a new position in Insulet Co. (NASDAQ:PODD) in the 3rd quarter, HoldingsChannel.com reports. The fund acquired 6,890 shares of the medical instruments supplier’s stock, valued at approximately $730,000. Insulet comprises about 0.5% of Campbell & CO Investment Adviser LLC’s investment portfolio, making the stock its 27th largest holding.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. FMR LLC increased its holdings in Insulet by 0.6% in the 2nd quarter. FMR LLC now owns 8,740,881 shares of the medical instruments supplier’s stock worth $749,093,000 after acquiring an additional 52,946 shares during the last quarter. OppenheimerFunds Inc. grew its holdings in Insulet by 26.6% during the 2nd quarter. OppenheimerFunds Inc. now owns 791,702 shares of the medical instruments supplier’s stock valued at $67,848,000 after buying an additional 166,585 shares in the last quarter. American Century Companies Inc. grew its holdings in Insulet by 737.9% during the 3rd quarter. American Century Companies Inc. now owns 700,892 shares of the medical instruments supplier’s stock valued at $74,260,000 after buying an additional 617,241 shares in the last quarter. Wasatch Advisors Inc. grew its holdings in Insulet by 37.4% during the 3rd quarter. Wasatch Advisors Inc. now owns 554,604 shares of the medical instruments supplier’s stock valued at $58,760,000 after buying an additional 150,948 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Insulet by 87.4% during the 2nd quarter. Millennium Management LLC now owns 532,109 shares of the medical instruments supplier’s stock valued at $45,602,000 after buying an additional 248,108 shares in the last quarter.

A number of research analysts have weighed in on the company. BidaskClub lowered Insulet from a “hold” rating to a “sell” rating in a report on Friday, October 12th. Zacks Investment Research lowered Insulet from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. Jefferies Financial Group reaffirmed a “buy” rating and set a $97.00 target price on shares of Insulet in a report on Friday, August 3rd. Oppenheimer set a $96.00 target price on Insulet and gave the company a “hold” rating in a report on Friday, August 3rd. Finally, Morgan Stanley lifted their target price on Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $101.20.

Shares of PODD opened at $81.73 on Friday. The stock has a market cap of $4.85 billion, a PE ratio of -177.67 and a beta of 1.67. The company has a quick ratio of 3.99, a current ratio of 4.58 and a debt-to-equity ratio of 2.95. Insulet Co. has a 12-month low of $67.43 and a 12-month high of $108.90.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The firm had revenue of $151.10 million during the quarter, compared to the consensus estimate of $148.82 million. Insulet had a negative return on equity of 7.63% and a negative net margin of 2.54%. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($0.04) EPS. On average, equities analysts forecast that Insulet Co. will post -0.05 earnings per share for the current year.

In other news, insider Shacey Petrovic sold 1,134 shares of Insulet stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $86.91, for a total transaction of $98,555.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Aiman Abdel-Malek sold 602 shares of Insulet stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $107.99, for a total value of $65,009.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,013 shares of company stock valued at $856,934. Corporate insiders own 3.60% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://sportsperspectives.com/2018/11/16/campbell-co-investment-adviser-llc-invests-730000-in-insulet-co-podd-stock.html.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Further Reading: How to calculate the intrinsic value of a stock

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply